Strategic Initiative

Slingshot members are tracking this corporate initiative:

ZioPharm announces potential point-of-care (POC) manufacturing of CAR-T cells using its Sleeping Beauty system

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The data presented showed T cells expressing CD19-specific CAR with membrane-bound IL-15 (mbIL15) were generated with the non-viral Sleeping Beauty system in less than two days and did not require ex vivoactivation or propagation. T cells designed to express mbIL15 showed greater persistence and more potent antitumor activity than comparator T cells without mbIL15 in these studies.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Feb 12, 2018
Projected Implementation:
Q1, 2018
Relevance Tracked Until:
Q2, 2018
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Car-t Cells, Il-15